Screen Reader Mode Icon
The objective of this survey is to clarify what are the areas highest in decision makers’ agenda in the field of bacterial, fungal and viral infectious diseases.
Information collected will be used in the framework of the EURIPHI EU H2020 project (GA n° 825922). Its aim is introducing innovative solutions using rapid diagnostics in care delivery by means of cross-border value-based innovation procurement.
Feedback will be used to know more about the interest of countries and regions to identify and prioritise unmet needs in the field of infectious diseases and to use innovative rapid diagnostics to face these unmet needs.
Therefore, feedback will help to understand whether these priorities are for ICUs (Intensive Care Units) and/or hospitals and/or community care settings.
Willingness to invest in innovative rapid diagnostics in the care pathway by Governments and regional/local health authorities will be explored as well.
With the information gathered, the EURIPHI consortium will:
  • Develop an overview of identification and prioritisation of unmet needs in the field of innovative rapid diagnostics for infectious diseases in Europe;
  • Update the Deliverable D1.1 ‘Mapping of Health Regions readiness for value-based PPI and mechanisms of identification of unmet health and health systems’ needs. Reflection paper of common vision on cross-border value-based PPI. Overview list of national-regional health authorities’ representatives for EURIPHI. Identification of current process of identification of unmet need’;
  • Identify the countries/regions willingness to co-invest in the field of innovative rapid diagnostics.

Question Title

* 1. Do health authorities in your country/region put in place mechanisms of identification of unmet needs for infectious diseases?

Question Title

* 2. Do health authorities in your country/region put in place mechanisms of prioritisation of unmet needs for infectious diseases?

Question Title

* 3. Please, indicate the name of country and region you are referring to.

Question Title

* 4. If yes, for which infectious diseases?

Question Title

* 5. Could you, please, prioritise and list the name of bacterial disease(s) for which such identification mechanisms are in place?

Question Title

* 6. Could you, please, prioritise and list the name of fungal disease(s) for which such identification mechanisms are in place?

Question Title

* 7. Could you, please, prioritise and list the name of viral disease(s) for which such identification mechanisms are in place?

Question Title

* 8. For the most relevant type of infections and disease area(s) identified in the previous response, please, indicate the care setting(s) they refer to. Please, use ICUs for Intensive Care Units, H for hospitals and CC for community care (e.g. bacterial infectious for respiratory diseases in ICUs).

Question Title

* 9. What is the responsible institution in your country/region for the identification and prioritisation of infectious diseases? Is it a Government and/or regional/local health authority?

Question Title

* 10. Are there, in general, investments available to introduce innovative rapid diagnostics for infectious diseases in your country?

Question Title

* 11. If yes, what are these investments about? What is their amount? What are the technologies involved?

0 of 11 answered
 

T